Phase 3 DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer

[at noodls] – Wayne, NJ and South San Francisco, CA. – Jan. 03, 2013 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar® (sorafenib) tablets in patients with … more

View todays social media effects on ONXX

View the latest stocks trending across Twitter. Click to view dashboard

See who ONYX is hiring next, click here to view